Trial Profile
A Single Arm Phase II Study of Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer: Big Ten Cancer Research Consortium BTCRC-BRE15-016
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Oct 2023
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary) ; Tamoxifen (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer
- Focus Proof of concept; Therapeutic Use
- 04 Oct 2023 Planned End Date changed from 1 Sep 2023 to 1 Nov 2023.
- 04 Oct 2023 Planned primary completion date changed from 1 Sep 2023 to 1 Nov 2023.
- 08 Sep 2023 Planned End Date changed from 1 Aug 2023 to 1 Sep 2023.